Arimoclomol Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 47 mg, 62mg, 93mg

Reference Brands: MIPLYFFA (USA)

Category: Orphan Drugs

Arimoclomol (brand name Miplyffa) is an orphan drug used for treating the neurological manifestations of Niemann-Pick disease type C (NPC) in patients aged 2 years and older. It works by enhancing heat-shock protein production, helping protect cells from stress and improving protein handling. Arimoclomol is available as oral capsules in multiple strengths and is used together with miglustat to slow neurological progression in NPC. Arimoclomol is available in Capsules and strengths such as 47 mg, 62mg, 93mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Arimoclomol is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Arimoclomol can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Arimoclomol is a prescription medication indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) when used in combination with miglustat in adults and pediatric patients aged 2 years and older. NPC is a rare, progressive genetic lysosomal storage disorder characterized by impaired lipid trafficking in cells, which leads to lipid accumulation in the brain and other organs, resulting in severe neurological and systemic symptoms. Arimoclomol works by enhancing the cellular heat shock response—boosting production of protective heat shock proteins (HSPs) that help maintain normal protein folding and assist in cellular stress management. It is orally administered in capsule form in weight-based doses, usually taken three times a day, and may be swallowed whole or opened and mixed with liquid or soft foods for patients with swallowing difficulties. Arimoclomol is notable for its ability to cross the blood–brain barrier, a critical feature for therapies targeting neurodegenerative processes. Common side effects include upper respiratory tract infection, diarrhea, and decreased weight. Arimoclomol was approved by the U.S. Food and Drug Administration in 2024 and represents a first-in-class treatment for NPC.